© 2005-2012 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.
Using the drop-down menu below, read about highlighted scientific news from ASCO's Annual Meetings since 2002. You can select a specific year and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
The 2013 ASCO Annual Meeting is set for May 31-June 4, with research news beginning to be released on May 15 at 6pm Eastern. Additional research will be released each day of the meeting.
To read these summaries categorized into a yearly newsletter, you can also review Cancer Advances: News for Patients from the ASCO Annual Meeting.
Don’t forget to check out audio podcasts and videos about this news, as well. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at the ASCO Annual Meeting. To search the entire collection of meeting abstracts, visit ASCO's website.
Results of a large phase II clinical trial show that a hormone drug called toremifene (Acopodene) lowers the risk of prostate cancer by nearly half for men with prostatic intraepithelial neoplasia (PIN).
A new study from the National Surgical Adjuvant Breast and Bowel Project (NSABP) shows that higher rates of breast cancer deaths for black women are not due to lower doses of chemotherapy. Black women are more likely to die from breast cancer than white women, but the reasons are unknown.
A new study reports that black women are more likely to experience delays in the diagnosis and treatment of breast cancer. These delays are significant because other studies have found that postponing treatment for three months or more can lower the five-year survival rate by 12%.
Results of the MRC Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial show that perioperative chemotherapy (the use of chemotherapy before and after surgery) improved overall survival and delayed cancer growth for people with operable cancer of the stomach and lower esophagus.
A study of more than 40,000 female veterans in the United States shows that the cholesterol-lowering drugs known as statins help reduce the risk of breast cancer by more than half.
A new drug, called AG-013736, is designed to treat metastatic renal cell cancer (a type of kidney cancer) that no longer responds to immunotherapy.
A phase III study led by the International Breast Cancer Study Group (IBCSG) shows that letrozole (Femara) is more effective than tamoxifen (Nolvadex) in preventing breast cancer recurrence (return of the cancer).
Results of a new study show that adding bevacizumab (Avastin) to chemotherapy helps people with non-small cell lung cancer (NSCLC) live longer. Bevacizumab stops angiogenesis, the process of forming new blood vessels, which helps tumors grow and spread.
Stage I seminoma is an early stage, slow-growing type of testicular cancer. The standard treatment is usually removal of the cancerous testicle (orchiectomy), followed by adjuvant radiation therapy. However, patients who receive radiation therapy also tend to have a higher risk of developing a second cancer in another organ 10 to 20 years later.
Two new studies demonstrate that docetaxel (Taxotere) extends survival and relieves pain in men with prostate cancer that does not respond to hormone therapy.